Pharmacogenomics and bioinformatics: PharmGKB

Pharmacogenomics

Volumn 11, Issue 4, 2010, Pages 501-505

  Thorn, Caroline F ^a   Klein, Teri E ^a   Altman, Russ B ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biocuration; Bioinformatics; Consortia; Gene variant; Pathway; Pharmacogenomics; PharmGKB

Indexed keywords

AMIODARONE; CLOPIDOGREL; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; TAMOXIFEN; THIOPURINE METHYLTRANSFERASE; WARFARIN;

BIOINFORMATICS; GENETIC VARIABILITY; GENOTYPE; INFORMATION PROCESSING; KNOWLEDGE BASE; NOTE; PHARMACOGENOMICS; PHENOTYPE;

COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DISEASE; DRUG THERAPY; INTERNET; KNOWLEDGE BASES; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 77950352522     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.15     Document Type: Note

References (28)

1. Klein TE, Chang JT, Cho MK et al.: Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J. 1(3), 167-170 (2001).
2. Lin Z, Owen AB, Altman RB: Genetics. Genomic research and human subject privacy. Science 305(5681), 183 (2004).
3. Rhead B, Karolchik D, Kuhn RM et al.: The UCSC genome browser database: update 2010. Nucleic Acids Res. 38(Database issue), D613-D619 (2009).
4. Wishart DS, Knox C, Guo AC et al.: DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34(Database issue), D668-D672 (2006).
5. Luciano JS: PAX of mind for pathway researchers. Drug Discov. Today 10(13), 937-942 (2005).
6. Giacomini KM, Brett CM, Altman RB et al.: The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin. Pharmacol. Ther. 81(3), 328-345 (2007).
7. Whirl-Carrillo M, Woon M, Thorn CF, Klein TE, Altman RB: An XML-based interchange format for genotype-phenotype data. Hum. Mutat. 29(2), 212-219 (2008).
8. Klein TE, Altman RB, Eriksson N et al.: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
9. Owen R P, Altman RB, Klein TE: PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics. Hum. Mutat. 29(4), 456-460 (2008).
10. Altman RB, Flockhart DA, Sherry ST, Oliver DE, Rubin DL, Klein TE: Indexing pharmacogenetic knowledge on the World Wide Web. Pharmacogenetics 13(1), 3-5 (2003).
11. Garten Y, Altman RB: Pharmspresso: a text mining tool for extraction of pharmacogenomic concepts and relationships from full text. BMC Bioinformatics 10(Suppl. 2), S6 (2009).
12. Sangkuhl K, Berlin DS, Altman RB, Klein TE: PharmGKB: understanding the effects of individual genetic variants. Drug Metab. Rev. 40(4), 539-551 (2008).
13. Yu W, Ned R, Wulf A, Liu T, Khoury MJ, Gwinn M: The need for genetic variant naming standards in published abstracts of human genetic association studies. BMC Res. Notes 2, 56 (2009).
14. Owen R P, Sangkuhl K, Klein TE, Altman RB: Cytochrome P450 2D6. Pharmacogenet. Genomics 19(7), 559-562 (2009).
15. Hildebrandt M, Adjei A, Weinshilboum R: et al.: Very important pharmacogene summary: sulfotransferase 1A1. Pharmacogenet. Genomics 19(6), 404-406 (2009).
16. Thorn CF, Klein TE, Altman RB: PharmGKB summary: very important pharmacogene information for angiotensin-converting enzyme. Pharmacogenet. Genomics 20(2), 143-146 (2009).
17. Hodges LM, Markova SM, Chinn LW et al.: Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet. Genomics PMID: 20216335 (2010) (Epub ahead of print).
18. Wang L, Pelleymounter L, Weinshilboum R et al.: Very important pharmacogene summary: thiopurine S-methyltransferase. Pharmacogenet. Genomics PMID: 20154640 (2010) (Epub ahead of print).
19. van Booven D, Marsh S, McLeod H et al.: Cytochrome P450 2C9-CYP2C9. Pharmacogenet. Genomics. PMID: 20150829 20(4), 277-281 (2010).
20. Oshiro C, Thorn CF, Roden DM, Klein TE, Altman RB: KCNH2 pharmacogenomics summary. Pharmacogenet. Genomics PMID: 20150828 (2010) (Epub ahead of print).
21. Medina M W, Sangkuhl K, Klein TE, Altman RB: PharmGKB: very important pharmacogene-HMGCR. Pharmacogenet. Genomics PMID: 20084049 (2010) (Epub ahead of print).
22. Owen RP, Gong L, Sagrieya H, Klein TE, Altman RB: VKORC1 pharmacogenomics summary. Pharmacogenet. Genomics PMID: 19940803 (2009) (Epub ahead of print).
23. Litonjua AA, Gong L, Duan QL et al.: Very important pharmacogene summary ADRB2. Pharmacogenet. Genomics 20(1), 64-69 (2010).
24. Berlin DS, Person MG, Mittal A et al.: DNATwist: a web-based tool for teaching middle and high school students about pharmacogenomics. Clin. Pharmacol. Ther. (2010) (In Press).
25. Crowley JJ, Sullivan PF, McLeod HL: Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics 10(2), 161-163 (2009).
26. Goldstein DB: Common genetic variation and human traits. N. Engl. J. Med. 360(17), 1696-1698 (2009).
27. Nelson MR, Bacanu SA, Mosteller M et al.: Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J. 9(1), 23-33 (2009).
28. Tabone T: Mutations, structural variations, and genome-wide resequencing: where to from here in our understanding of disease and evolution? Hum. Mutat. 29(6), 886-890 (2008).